IDH2 and astrocytoma (excluding glioblastoma): In IDH-mutant astrocytomas, these gene panels were able to reproducibly identify a subset of IDH-mutant astrocytomas (27.4%) with evidence of CIN, which corresponded to significantly elevated copy number burden at initial biopsy/resection (irrespective of WHO grade), and significantly reduced progression-free survival (PFS) and overall survival (OS) intervals [97].